Clinical trial
An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05908396 is registered in ClinicalTrials.gov with IGM Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Lead sponsor
- IGM Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 29, 2023
- Completion date
- February 16, 2024
- Enrollment
- 4 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.